Sarcoma

    Actionable Targets Tumor Prevalence (%) Clinical Experience with Targeted Agent
    EML4-ALK
    DCTN1-ALK
    RANBP2-ALK
    Inflammatory myofibroblastic tumor  50 Crizotinib (ALK/ROS1 inhibitor):
    • Case report: PR in 1 pt for 6+ mo (10)COG Phase I: 3 of 7 pts (all 3 received >11 cycles on study (11))
    Crizotinib (ALK inhibitor):
    • Case report, with pazopanib (VEGFR inhibitor): PR in 1 pt for 6+ mo (12)
    Ceritinib (ALK inhibitor):
    • Phase I: 1 pt with PR (13)
    Alectinib (ALK inhibitor):
    • Case report: PR in 1 pt for 4+ mo (14)
    ASPSCR1-TFE3 (ASPL-TFE3)
    Other topics in Targets by Organ Site